Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cipher Mining Inc (CIFR) vs Enveric Biosciences Inc (ENVB) Price & Performance

Cipher Mining IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Cipher Mining Inc vs Enveric Biosciences Inc — how do they compare? Cipher Mining Inc trades at $20.14 (market cap $8.13B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Cipher Mining Inc is far larger — about 1528.2× Enveric Biosciences Inc's market cap, and Cipher Mining Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

CIFRENVB
Market Cap
$8.13B$5.32M
Sector
Basic MaterialsHealth
52-Week High
$29.18$17.40
52-Week Low
$4.72$1.28
Enterprise Value
$12.16B$408.82K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cipher Mining Inc

CIFR trades at $20.085, down 9.16% over 24 hours, reflecting bearish technical signals despite unanimous analyst buy ratings. The company is transitioning from Bitcoin mining to AI data center operations, evidenced by a $11.4B contracted revenue backlog but faces significant financial strain with a -427.79% net income margin and negative cash flow from operations. Recent news highlights volatility driven by AI infrastructure developments and capital raises.

The outlook hinges on successful execution of its AI data center pivot, offering substantial upside to the $32.81 consensus price target, but high valuation multiples and persistent losses pose near-term risks. Investors must weigh transformative growth potential against cash burn and execution challenges in a competitive sector.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

About Cipher Mining Inc

Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.

Read more on CIFR

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB